A Stanford StartX Company; Future Cardia, Advances Implantable Cardiac Monitor After European Clinical Use
Future Cardia a Stanford StartX-accelerated medtech startup has completed clinical use of its implantable cardiac monitor in Europe, with 39 successful implants and over 60,000 hours of real-world heart rhythm data collected.
Designed for long-term, passive monitoring, the device targets patients with hard-to-detect or intermittent cardiac symptoms, offering a more continuous and actionable alternative to traditional external monitors; a $40B a year healthcare problem.
Focused on the World’s Most Prevalent Health Issue
Heart disease remains the world’s leading cause of death, and Future Cardia aims to address critical gaps in cardiac diagnostics with technology that stays in place for extended periods and captures richer patient data.
Institutional Support and Experienced Team
Accelerated by Stanford StartX and incubated J&J’s JLABS, and led by alumni from Medtronic, Boston Scientific, and Stanford, the team brings over 200 years of device experience to the table.
The company has raised $14M+ from 10,000+ investors via equity crowdfunding and is currently closing its round on StartEngine.
Offering Period Ending Soon
Future Cardia’s current fundraising campaign is expected to close soon. The company is continuing to engage with investors through its listing on StartEngine, where it has provided updates on its recent clinical activity and milestones.
While commercialization timelines have not been announced, Future Cardia’s recent clinical data and institutional backing position it as one of several companies exploring long-term, device-based solutions in the cardiac care space.
*This product is not yet available for purchase and requires review and clearance before being marketed or sold. This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.